Gestational Diabetes Mellitus

Metabolic Diseases
5
Pipeline Programs
3
Companies
4
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 3 programs with unclassified modality

On Market (2)

Approved therapies currently available

Novo Nordisk
SAXENDAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2014
Novo Nordisk
VICTOZAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2010

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
3 programs
1
2
LiraglutidePhase 4Peptide1 trial
MetforminPhase 41 trial
Metformin XR plus placeboPhase 31 trial
Active Trials
NCT01234649Completed153Est. Jun 2019
NCT01795248Completed105Est. Sep 2020
NCT02394158Unknown112Est. Sep 2019
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
Gestational Diabetes Mellitus and Cardiometabolic Syndrome in OffspringN/A1 trial
Active Trials
NCT01490372Completed41Est. May 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo NordiskMetformin
Novo NordiskLiraglutide
Novo NordiskMetformin XR plus placebo
Eli Lilly and CompanyGestational Diabetes Mellitus and Cardiometabolic Syndrome in Offspring

Clinical Trials (4)

Total enrollment: 411 patients across 4 trials

Preventing Recurrent Gestational Diabetes With Metformin

Start: Jan 2015Est. completion: Sep 2019112 patients
Phase 4Unknown

The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes

Start: Jul 2012Est. completion: Sep 2020105 patients
Phase 4Completed
NCT01234649Novo NordiskMetformin XR plus placebo

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Start: Aug 2011Est. completion: Jun 2019153 patients
Phase 3Completed
NCT01490372Eli Lilly and CompanyGestational Diabetes Mellitus and Cardiometabolic Syndrome in Offspring

Gestational Diabetes Mellitus and Cardiometabolic Syndrome in Offspring

Start: Aug 2011Est. completion: May 201341 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space